PF-3654746

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-3654746
Drug Alias NamePF-03654746PF-0354746PF-3654746
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H3 receptor antagonists
TargetsHistamine H3 receptor
Therapy Area/IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityNarcolepsy +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingapore
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityNarcolepsy +[7] 

Other Information

ATC CodeN/A
Related LinksN/A